MichaelATraunerMD
Dermatology • Ventura, CACosmetic Dermatology, Dermatologic Surgery
Premier Dermatology & Mohs Surgery Center
Dr. Trauner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5855 Olivas Park Dr
Ventura, CA 93003Phone+1 805-667-2801
Summary
- Dr. Michael Trauner is a dermatologist in Ventura, CA. He received his medical degree from Duke University School of Medicine and has been in practice 20 years. He specializes in cosmetic dermatology and dermatologic surgery and is experienced in dermatologic surgery, cosmetic dermatology, and Mohs micrographic surgery.
Education & Training
University of California Davis HealthResidency, Dermatology, 1997 - 2000
Kaiser Permanente Northern California (Santa Clara)Internship, Internal Medicine, 1994 - 1995
Duke University School of MedicineClass of 1994
Certifications & Licensure
CA State Medical License 1995 - 2025- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Fellow (FAAD) American Academy of Dermatology
- Fellow (FASDS) American Society for Dermatologic Surgery
Clinical Trials
- Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis Start of enrollment: 2012 Dec 01
- Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD Start of enrollment: 2013 May 01
- norUrsodeoxycholic Acid vs Placebo in PSC Start of enrollment: 2018 Feb 08
Publications & Presentations
PubMed
- 23 citationsFXR agonists in NASH treatment.Luciano Adorini, Michael Trauner
Journal of Hepatology. 2023-11-01 - 15 citationsSafety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.Michael Trauner, Christopher L Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H Caldwell
Clinical Gastroenterology and Hepatology. 2023-06-01 - 11 citationsPRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic pa...Michael Trauner, Chuhan Chung, Kate Sterling, Xiangyu Liu, Xiaomin Lu
BMC Gastroenterology. 2023-03-15
Press Mentions
Time to Screen for Liver Disease in Type 2 Diabetes?October 5th, 2020
NUDCA Analog Shows Promise in NAFLDJuly 29th, 2019
Gilead Announces Positive Phase 2 Results for GS-9674 in Primary Sclerosing Cholangitis (PSC) at the Liver MeetingNovember 9th, 2018- Join now to see all
Professional Memberships
- Fellow
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
